2024 – 2027 Support for Cancer Clinical Trials Program Grant Opportunity

Overview

The Support for Cancer Clinical Trials Program (the program) will run over three years from 2024-25 to 2026-27. The program provides funding to Australia's Multi-site Collaborative Cancer Clinical Trials Groups (CTGs) to develop investigator-initiated and industry-independent cancer clinical trial protocols that will contribute to delivering on the objectives of the program. In November 2023, the Minister for Health and Aged Care released the Australian Cancer Plan (the Plan). The Plan is designed to improve cancer outcomes for all Australians, and particularly for those groups whose health outcomes are poorest. Achieving equity in cancer outcomes will be a fundamental measure of success for the Plan and will align Australia with global calls to improve cancer outcomes for all people. The program will support the delivery of the Plan by ensuring targeted and innovative research investment into areas of unmet and emerging need; improving clinical trial design, including methods to improve equitable access to trials and accelerate translation of innovative research into clinical practice. The objectives of the program are to increase: The number of cancer clinical trials conducted in Australia. Participation in clinical trials by people affected by cancer. The number of clinical sites actively participating in cancer clinical trials. The involvement of policy makers, clinicians, researchers and consumers in the development of cancer clinical trials. CTG participation in national multi-group or international cancer clinical trials in Australia. The intended outcomes of the program are to: Guide scientific improvements in cancer prevention, treatment and care. Build the evidence-base for best practice cancer care across all aspects of the cancer continuum. Reduce cancer incidence and mortality. Achieve equity in cancer outcomes and improve quality of life for Australians affected by cancer.